Bifogade filer
Beskrivning
Land | Norge |
---|---|
Lista | 12 |
Sektor | Hälsovård |
Industri | Bioteknik |
Genetic Analysis AS' ("GA" or the "Company") subsequent offering to existing shareholders, for which the subscription period ended on June 16, 2025 (the "Subsequent Offering"), has now been registered with the Norwegian Register of Business Enterprises (No. Foretaksregisteret).
During the period June 5 - June 16, 2025, GA carried out the Subsequent Offering that provided the Company with approximately NOK 4.1 million by issuance of 4,813,194 new shares, before issue costs. The Subsequent Offering has now been registered with the Norwegian Register of Business Enterprises.
After this, the Company's new registered share capital is NOK 41,452,224.60 divided into 69,087,041 shares, each with a nominal value of NOK 0.60.
Advisors
In connection with the Subsequent Offering, Sedermera Corporate Finance AB (www.sedermera.se) is appointed Swedish financial advisor and Advokatfirmaet Wiersholm AS is the Company's Norwegian legal advisor.